These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 3053059)
21. [Preclinical study of therapeutic agents used against Mycobacterium avium complex infections--with special reference to new macrolides and new quinolones]. Tomioka H; Sato K; Saito H Kekkaku; 1996 Sep; 71(9):531-5. PubMed ID: 8999135 [No Abstract] [Full Text] [Related]
22. [Chemotherapeutics. 7. Chemotherapy of bacterial infections. Chemotherapy of protozoan infections. Chemotherapy of virus infections]. Mayr E Pharm Prax; 1967; 7():163-93. PubMed ID: 4893524 [No Abstract] [Full Text] [Related]
23. Clinical Microbiology and Infectious Diseases (ECCMID)--18th European Congress. New antimicrobial agents: selected poster presentations. Northwood JB IDrugs; 2008 Jun; 11(6):405-8. PubMed ID: 18509778 [No Abstract] [Full Text] [Related]
24. [Pneumonia due to Legionella. Macrolides or quinolones?]. Gómez J; Ruiz Gómez J; Sabrià M Rev Esp Quimioter; 2002 Mar; 15(1):21-4. PubMed ID: 12582433 [No Abstract] [Full Text] [Related]
26. [Combined use of quinolones with other antibiotics in treatment of experimental plague infection]. Shcherbaniuk AI; Kasatkina IV; Ryzhko IV Antibiot Khimioter; 1994 May; 39(5):38-40. PubMed ID: 7857159 [TBL] [Abstract][Full Text] [Related]
27. New and future antibiotics in the treatment of acute respiratory tract infections. Wise R Thorax; 1995 Mar; 50(3):223-4. PubMed ID: 7660331 [No Abstract] [Full Text] [Related]
28. Antibiotic drug interactions. Pai MP; Momary KM; Rodvold KA Med Clin North Am; 2006 Nov; 90(6):1223-55. PubMed ID: 17116445 [TBL] [Abstract][Full Text] [Related]
30. Selecting antibacterial agents for the control of surgical infection: mini-review. Periti P; Tonelli F; Mini E J Chemother; 1998 Apr; 10(2):83-90. PubMed ID: 9603631 [TBL] [Abstract][Full Text] [Related]
31. New macrolides or new quinolones as monotherapy for patients with community-acquired pneumonia: our cup runneth over? Yu VL; Vergis EN Chest; 1998 May; 113(5):1158-9. PubMed ID: 9596286 [No Abstract] [Full Text] [Related]
34. [New quinolones for the treatment of community-acquired pneumonia--pro]. Zimmerli S Dtsch Med Wochenschr; 2003 May; 128(19):1070. PubMed ID: 12736859 [No Abstract] [Full Text] [Related]
35. Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group. Krumpe PE; Cohn S; Garreltes J; Ramirez J; Coulter H; Haverstock D; Echols R J Antimicrob Chemother; 1999 Mar; 43 Suppl A():117-28. PubMed ID: 10225582 [TBL] [Abstract][Full Text] [Related]
36. Sequential or switch treatment - which criteria should be fulfilled? Shah PM Int J Antimicrob Agents; 2000 Nov; 16(3):301-2. PubMed ID: 11091052 [No Abstract] [Full Text] [Related]
37. Present situation of multidrug-resistant tuberculosis in Asian countries and the possibility of MDR-TB treatment by new quinolones. Proceedings of a satellite symposium for the 14th Asia Pacific Congress on Diseases of the Chest. Bali, June 26, 1996. Chemotherapy; 1996; 42 Suppl 3():1-35. PubMed ID: 9072462 [No Abstract] [Full Text] [Related]
38. A guide to the treatment of lower respiratory tract infections. Vogel F Drugs; 1995 Jul; 50(1):62-72. PubMed ID: 7588090 [TBL] [Abstract][Full Text] [Related]
39. [Antibiotics, developments and orientation]. de Marie S; Verbrugh HA Ned Tijdschr Geneeskd; 1992 Apr; 136(14):673-8. PubMed ID: 1560853 [No Abstract] [Full Text] [Related]